2-MMC
2-methylmethcathinone
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
2-MMC (2-methylmethcathinone) — ortomephedrone — is a synthetic stimulant of the substituted cathinone class. It is a close structural variant of mephedrone, with a shorter duration and less emotional warmth. It floods synapses with dopamine, norepinephrine, and serotonin, producing the drive and euphoria typical of powerful stimulants.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
amphetamine, methamphetamine, MDMA +3 moreamphetamine, methamphetamine, MDMA, 3-MMC, mephedrone, cocaine show less
2-MMC entered European drug markets in 2013, synthesized to sidestep bans on mephedrone.[3] It surged as a direct replacement for 3-MMC after the Netherlands banned that compound in 2021 — 83.4% of EU seizures occurred in 2024, and half of samples sold as 3-MMC that year actually contained 2-MMC.[4] EU-wide drug control took effect January 2026.[5]
Subjective effects include stimulation, euphoria, sociability, appetite suppression, and wakefulness.[6] The experience is that of a restless, drive-focused stimulant — sharper than mephedrone but with less emotional warmth, defined above all by a powerful compulsive redosing urge that shapes the entire session.[7] Anxiety, rapid heartbeat, and a hard post-use crash with low mood and fatigue are common unwanted effects.
2-MMC carries high risk for psychological dependence — its short action, powerful redosing urge, and dopamine-heavy pharmacology drive binge patterns that compound cardiovascular strain[8] and monoamine depletion.[2][7] Treatment-seeking for the closely related 3-MMC rose tenfold in the Netherlands in two years,[7] a measure of the real-world harm. No controlled human studies exist — the evidence base is forensic data, class pharmacology, and user reports.
History[edit]
Discovery
2-MMC was created through isomer substitution — shifting a methyl group on the aromatic ring to evade drug controls targeting mephedrone.[3][9] It was first detected in Germany in 2013, with the earliest documented seizure occurring in Stockholm in March 2014.[4]
Market proliferation
When the Netherlands banned 3-MMC in October 2021, 2-MMC immediately filled the gap. Of 1,900 total EU seizure cases, 1,587 (83.4%) occurred in 2024 alone.[4] Drug checking services in early 2024 found that 50% of samples sold as 3-MMC actually contained 2-MMC.[4]
Prohibition and current status
EU Delegated Directive 2025/2062 placed 2-MMC under EU-wide drug control on 12 January 2026, with member states required to implement national legislation by July 2026.[5][4]
The name ortomephedrone reflects 2-MMC's structural relationship to mephedrone — the prefix orto- denotes the 2-position of the methyl substituent. On unregulated markets it frequently circulates under the 3-MMC label: forensic analysis confirmed 12 of 15 Belgian samples initially attributed to mephedrone actually contained 2-MMC.[10] Standard immunoassays and basic mass spectrometry struggle to differentiate positional isomers,[3] making 2-MMC a persistent identification challenge for both users and clinicians.
Chemistry[edit]
Structure
2-MMC belongs to the substituted cathinone family — β-keto amphetamines — within the broader phenethylamine class. Its molecular formula is C₁₁H₁₅NO, identical to 3-MMC and mephedrone; all three are positional isomers that differ only in where the methyl group sits on the aromatic ring — at the 2-position (ortho) for 2-MMC.
Stereochemistry
The molecule has two mirror-image forms (enantiomers), and both have been detected in oral fluid samples from confirmed users.[10] For the closely related mephedrone, one enantiomer shows significantly greater reinforcing properties in animal models[11] — whether this extends to 2-MMC is unknown.
Pharmacology[edit]
Mechanism of action
No binding data have been published for 2-MMC directly. Based on its close structural relatives 3-MMC and mephedrone, it is classified as a non-selective monoamine releasing agent. It enters nerve terminals and reverses the dopamine, norepinephrine, and serotonin transporters, forcing those neurotransmitters out into the synapse.[1][2][12]
The 2- and 3-MMC isomers show similar dopamine activity but reduced serotonin activity compared to mephedrone.[7] Substances that hit dopamine harder than serotonin tend to be more addictive and produce less emotional warmth.[2] This classification rests entirely on structural analogy — no laboratory studies have been conducted specifically on 2-MMC.safety citation needed
Pharmacokinetics
Two metabolites have been identified in oral fluid from confirmed users[10]: nor-2-MMC and dihydro-2-MMC. By analogy with 3-MMC, the liver enzymes CYP2D6 and CYP2E1 are the most likely metabolic candidates[13] — people who metabolize drugs slowly through CYP2D6 (5–10% of European populations) may experience different drug exposure and toxicity profiles.
Neuroscience[edit]
Where it acts
As a dopamine-dominant monoamine releaser,[7] 2-MMC drives its primary effects through the brain's mesolimbic pathway. Dopamine release produces the subjective sense of reward and motivation; concurrent norepinephrine release drives stimulant arousal — elevated heart rate, wakefulness, and alertness. The reduced serotonin component, relative to mephedrone, predicts less emotional openness and a more purely restless, drive-oriented experience.[6]
Why it matters
2-MMC's high dopamine-to-serotonin ratio preferentially drives wanting over liking — intense craving even as the pleasure from each dose diminishes.[7] With repeated use, dopamine receptors downregulate, baseline dopamine production falls, and normal mood states begin to feel insufficient.[7]
Animal studies show that concurrent alcohol use roughly doubles cathinone-related neurotoxic damage to dopamine and serotonin systems in the frontal cortex.[14]
Key unknowns include whether the ortho-methyl position produces meaningfully different transporter kinetics than the meta- or para-positions, whether 2-MMC causes lasting dopaminergic neurotoxicity at typical recreational doses, and whether neuroadaptive changes from repeated use are reversible — and on what timescale.
Subjective Effects[edit]
2-MMC produces restless, drive-focused stimulation. The experience centers on physical energy, verbal fluency, and euphoria — a compulsive forward momentum rather than emotional warmth. Its most consistent defining feature is an intense compulsive redosing urge as each dose fades.[7]
Within the methylmethcathinone series, 2-MMC sits closer to the pure stimulant pole than mephedrone, which blends stimulant and empathogenic qualities. Compared to amphetamine, it is shorter-acting with a sharper euphoric peak but faster hedonic decline — a profile that favors binge patterns over sustained use.
Effect Grid
Full stimulant profile emerges — clear euphoria, marked energy increase, and pronounced sociability enhancement with increased talkativeness. Cognitive euphoria and thought acceleration are evident. Focus enhancement may be present, along with motivation enhancement. Music enhancement is reported by some users.
Sympathomimetic effects become apparent: tachycardia, elevated blood pressure, pupil dilation, and appetite suppression are prominent. Bruxism may emerge. Excessive sweating and temperature dysregulation begin at this level. Dry mouth is common.
The compulsive redosing urge becomes noticeable — the short duration of 2-MMC drives a pattern of repeated dosing that is the defining behavioral feature of use at this range. Insomnia is likely for several hours post-dose.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration · Visual acuity enhancement · Sound sensitivity · Tinnitus
Dry mouth · Heart rate perception changes · Insomnia · Pupil dilation · Body high · Dehydration sensation · Muscle tension · Physical fatigue · Restlessness · Bruxism · Excessive sweating · Respiratory stimulation · Tactile euphoria · Headache · Nasal congestion · Sexual arousal enhancement · Spontaneous body sensations · Tingling / electric sensations · Motor control enhancement · Dizziness · Laughter fits · Nausea · Trembling · Involuntary body movements · Vomiting
Body high · Dehydration sensation · Muscle tension · Physical fatigue · Restlessness · Bruxism · Excessive sweating · Respiratory stimulation · Tactile euphoria · Headache · Nasal congestion · Sexual arousal enhancement · Spontaneous body sensations · Tingling / electric sensations · Motor control enhancement · Dizziness · Laughter fits · Nausea · Trembling · Involuntary body movements · Vomiting
Motivation enhancement · Pattern recognition enhancement · Focus enhancement · Information processing enhancement · Aesthetic enhancement · Analysis enhancement · Cognitive dysphoria · Cognitive flexibility · Creativity enhancement · Immersion enhancement · Language enhancement · Motivation suppression · Novelty enhancement · Openness enhancement · Thought connectivity · Thought organization · Humor enhancement · Memory enhancement · Thought loops · Cognitive impairment · Confusion · Thought disorganization
Aesthetic enhancement · Analysis enhancement · Cognitive dysphoria · Cognitive flexibility · Creativity enhancement · Immersion enhancement · Language enhancement · Motivation suppression · Novelty enhancement · Openness enhancement · Thought connectivity · Thought organization · Humor enhancement · Memory enhancement · Thought loops · Cognitive impairment · Confusion · Thought disorganization
Emotional enhancement · Empathy enhancement · Irritability · Dysphoria · Emotional lability
Emotional lability
Communication enhancement · Sociability enhancement · Emotional susceptibility · Trust enhancement · Flow state · Ego inflation
Flow state · Ego inflation
Timeline
Initial alertness emerges with mild peripheral stimulation — a faint heart rate increase and subtle restlessness. Effects may be difficult to distinguish from anticipation.
Rising euphoria and energy. Sociability enhancement begins, conversation flows more easily. Appetite suppression starts.
Maximum euphoria and stimulation. Sociability enhancement at its strongest, thought acceleration prominent, appetite absent. Tachycardia and bruxism may be noticeable.
Stimulation persists but euphoria declines. The redosing urge intensifies as hedonic return diminishes. Residual sympathomimetic effects (elevated heart rate, sweating) continue.
Stimulation fades unevenly. Irritability and mild dysphoria emerge. Physical fatigue begins despite residual wakefulness.
Residual fatigue, mild dysphoria, and impaired concentration. Appetite returns. Insomnia may persist despite subjective tiredness.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Negligible
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · MDMA
Toxicity
No lethal dose data or controlled toxicology studies exist for 2-MMC in any species. All toxicity assessment derives from data on related cathinones, primarily 3-MMC and mephedrone.
Heart and circulation
Cardiovascular toxicity is the most significant acute danger. A retrospective analysis of 222 cathinone poisonings found elevated heart rate, high blood pressure, palpitations, and chest pain as the most common presentations.[8] Serious cardiac events documented across the cathinone class include cardiac arrest (28 published cases), dangerous heart rhythms, heart attacks, and heart muscle inflammation.
2-MMC shares the same norepinephrine-driven mechanism of cardiovascular stress.
Liver toxicity
Laboratory studies on 3-MMC show it damages liver cells through oxidative stress at concentrations within the range expected from human use.[13] 2-MMC is expected to share this vulnerability, though direct testing has not been performed.safety citation needed
Brain and nervous system
A systematic review of 76 studies found synthetic cathinones associated with brain swelling, seizures, coma, serotonin syndrome — a potentially life-threatening overheating and seizure response — and excited delirium.[15] Combining cathinones with alcohol roughly doubles the neurotoxic damage to dopamine and serotonin systems in animal models.[14]
Stimulant toxidrome
The expected acute toxicity pattern, based on confirmed 3-MMC data, includes: elevated heart rate (48%), agitation (42%), reduced consciousness (32%), dilated pupils (24%), hallucinations (20%), heavy sweating (12%), seizures (8%), and dangerously high body temperature (6%).[16][17][18] These rates are approximate class estimates for 2-MMC.safety citation needed
Testing cross-reactivity
2-MMC produces false-positive amphetamine results on standard hospital drug screens at concentrations ≥50 μg/mL.[19] Cathinone poisoning may be misidentified as amphetamine toxicity in emergency departments relying on immunoassay screening without confirmatory testing.
No antidote exists. Emergency treatment is supportive: benzodiazepines for agitation and seizures, active cooling for dangerously high body temperature, and cardiac monitoring.[16]
Psychological risks
Acute effects include agitation, anxiety, paranoia, and hallucinations — consistent with excessive dopamine activity.[15] Higher doses can produce paranoid beliefs and persecutory delusions, linked to prolonged use, sleep deprivation, and polydrug combinations.[16]
The post-use crash involves temporary monoamine depletion — low mood, irritability, fatigue, and difficulty feeling pleasure. The compound's short duration and intense redosing urge[7] drive binge sessions in which escalating doses compound both acute toxicity and the severity of the crash.
Treatment-seeking for closely related 3-MMC rose from 33 to 330 individuals annually in the Netherlands between 2021 and 2023.[7]
Tolerance & dependence
Tolerance to euphoric effects develops through compensatory changes in dopamine receptors. The rate for 2-MMC is uncharacterized. Cross-tolerance with other monoamine releasers — amphetamines, MDMA, 3-MMC, mephedrone — is expected.
The pharmacological profile — high dopamine activity, short duration, strong compulsive redosing urge — places 2-MMC in the high-risk category for psychological dependence.[2][1] The 2- and 3-MMC isomers produce greater craving and more frequent redosing than mephedrone,[7] a compound already recognized for significant abuse potential.
Withdrawal has not been characterized for 2-MMC. By class analogy, expect fatigue, excessive sleep, appetite enhancement, low mood, and craving. Physical withdrawal is not life-threatening, but psychological withdrawal — particularly craving and anhedonia — may be prolonged.[16]
Drug interactions
No interaction data have been published specifically for 2-MMC.safety citation needed
Monoamine oxidase inhibitors (MAOIs — including phenelzine, tranylcypromine, moclobemide, and plant-derived harmine/harmaline) represent the most dangerous combination. MAOIs prevent monoamine breakdown; combined with 2-MMC, monoamines accumulate to dangerous levels, causing fatal blood pressure spikes, serotonin syndrome, and extreme hyperthermia. This combination is life-threatening.
Serotonin-active medications (SSRIs, SNRIs, triptans, tramadol, lithium) carry additive serotonergic risk. Although 2-MMC's reduced serotonin activity[7] may partially attenuate this, serotonin syndrome remains possible at high doses or with strong serotonergic co-medications.
Other stimulants (amphetamines, cocaine, MDMA, other cathinones) add cardiovascular strain and compound neurotoxicity. Combining 2-MMC with MDMA produces dual-source serotonin release with elevated serotonin syndrome risk.
Alcohol is the most common co-ingestant — approximately 95% of cathinone users report concurrent alcohol use.[14] Alcohol combined with mephedrone produces roughly double the neurotoxic damage in animal models.[14] It also impairs judgment, increasing the likelihood of compulsive redosing.
GHB/GBL combined with stimulant cathinones is documented in chemsex fatalities involving 3-MMC.[18] The stimulant masks GHB's sedating effects; when the stimulant wears off, respiratory depression may emerge.
CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, bupropion) may alter 2-MMC metabolism and increase exposure to toxic metabolites.[13]
Contraindications
No substance-specific data exist. All contraindications are mechanism-based.
Heart conditions — coronary artery disease, heart failure, uncontrolled high blood pressure, structural heart defects, and history of abnormal heart rhythm — are an absolute contraindication. Cathinone-induced norepinephrine release drives dose-dependent increases in heart rate and blood pressure; serious cardiac events are documented across the class.[8]
Concurrent MAOI use is an absolute contraindication due to risk of fatal blood pressure crisis and serotonin syndrome.
Seizure disorders are a relative contraindication. Seizures occur in approximately 8% of cathinone poisoning presentations,[18] and monoamine releasers lower seizure threshold.
Liver impairment is a relative contraindication — impaired clearance may increase exposure to toxic metabolites.[13]
Mental health vulnerability — active psychosis, bipolar disorder, severe anxiety — is a relative contraindication. Dopaminergic stimulation can precipitate or worsen psychotic symptoms, manic episodes, and panic attacks.[15]
Pregnancy and breastfeeding are absolute contraindications. No reproductive data exist for 2-MMC, but stimulants carry risks of reduced placental blood flow, fetal distress, and preterm labor.safety citation needed
Hot environments, vigorous activity, and dehydration compound the risk of dangerously elevated body temperature, documented in 6% of 3-MMC poisoning presentations.[18]
Harm Reduction[edit]
Forms & Identification
The central harm reduction challenge with 2-MMC is identity uncertainty. Standard reagent kits and basic lab tests cannot distinguish between 2-MMC, 3-MMC, and mephedrone — all three produce identical reagent color reactions. Only advanced analytical services (GC-MS, LC-MS/MS, or NMR) can confirm which isomer is present.
Any powder sold as 3-MMC or mephedrone may contain 2-MMC, and vice versa. Drug checking data confirm this is the market norm, not a theoretical risk.[4] Use a drug checking service with advanced analytical capability wherever available.
Guidelines
- Test all material with an advanced drug checking service before use — reagent kits cannot distinguish the methylmethcathinone isomers
- Pre-measure and separate doses before beginning a session; do not carry the full supply
- Set a firm limit on total doses and session duration before starting — the redosing urge is the primary risk vector
- Start with a low oral dose and wait for full onset before considering re-administration
- Keep hydrated but avoid excessive water intake — moderate, regular sips
- Have a trusted person present who is not using and can monitor time, temperature, and behavior
- Eat a light meal beforehand; appetite suppression during the session makes retrospective nutrition harder
- Plan for the comedown: have food, water, and a comfortable rest space ready
Set & Setting
The short duration and intense redosing urge are the defining risk factors. Sessions easily escalate beyond intended limits when each dose wears off quickly and the compulsion to take more is strong.
A calm, familiar environment with trusted people present reduces the risk of anxiety, paranoia, and impulsive redosing. Avoid hot, crowded, or physically demanding settings — these compound the risk of dangerously elevated body temperature and cardiovascular strain.
Aftercare & integration. The comedown from 2-MMC involves monoamine depletion — the brain's supply of dopamine, norepinephrine, and serotonin is temporarily reduced. Expect low mood, fatigue, irritability, and difficulty feeling pleasure for 1–3 days after use.
Physical recovery: Prioritize sleep. Eat nutritious meals — appetite suppression during use means the body needs replenishment. Stay hydrated. Light exercise can support mood recovery; avoid anything strenuous for 24–48 hours.
Psychological recovery: The crash is temporary. Intense cravings during the comedown are a pharmacological effect — recognize them as the drug's signature and let them pass. If low mood, anxiety, or cravings persist beyond a week, speak to a healthcare provider.
Recovery & Support
The high compulsive redosing urge and short duration of 2-MMC create a use pattern that can escalate quickly from occasional sessions to regular binge use. Treatment-seeking for the closely related 3-MMC rose tenfold in the Netherlands in just two years.[7]
Warning signs of problematic use include: using more frequently or in larger amounts than intended, difficulty stopping once a session begins, neglecting responsibilities or relationships, persistent low mood between sessions, and continued use despite negative consequences.
Support resources include addiction helplines, harm reduction services, and mental health professionals experienced with stimulant use disorders. Cognitive behavioral therapy and motivational interviewing have evidence for stimulant dependence. Most people seeking treatment for methylmethcathinone use also use other substances[7] — comprehensive assessment covering all substances is more effective.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Chest pain or tightness
- Seizure or loss of consciousness
- Extreme overheating — body temperature you can feel through clothing
- Severe confusion, aggression, or complete disconnection from reality
- Breathing difficulties
Any of these requires immediate action — they distinguish a medical emergency from an uncomfortable but manageable experience.
Immediate steps:
- Call emergency services immediately
- Do not leave the person alone
- If unconscious and breathing, place in the recovery position (on their side)
- If overheating, move to a cool area, remove excess clothing, apply cool (not ice-cold) water
- Do not restrain unless there is immediate danger of self-harm
- Do not induce vomiting
What to tell the dispatcher:
Name the substance (or "a stimulant cathinone" if uncertain), the amount taken, the time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for cathinone poisoning. Treatment is entirely supportive.
Legal Status[edit]
2-MMC exploited the positional isomer loophole for over a decade, evading controls targeting mephedrone and later 3-MMC, until EU-wide control took effect in January 2026.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| European Union | Controlled substance (EU Delegated Directive 2025/2062) | EU-wide control from 12 January 2026; national implementation deadline 12 July 2026[5] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Blanket ban on psychoactive substances; production, supply, and import prohibited; simple possession not an offence under PSA unless in a custodial institutioncitation needed |
| United States | Not specifically scheduled | Potentially prosecutable under the Federal Analogue Act (21 USC §813) if demonstrated to be substantially similar to a Schedule I cathinone and intended for human consumptioncitation needed |
| China | Controlled substance | National drug control since October 2015[4] |
| Australia | Schedule 9 — Prohibited Substance | Illegal to manufacture, possess, sell, or usecitation needed |
| Netherlands | Controlled (EU implementation pending) | 3-MMC prohibited under Opium Act since October 2021; 2-MMC control expected under EU directive by July 2026[4] |
Legal status changes frequently and varies by jurisdiction. This entry was current as of early 2026 and does not constitute legal advice.
references
- [1] ^abcSimmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
- [2]
- [3] ^abcMaas A, Sydow K, Madea B, Hess C (2017) Separation of ortho, meta and para isomers of methylmethcathinone (MMC) and methylethcathinone (MEC) using LC-ESI-MS/MS: Application to forensic serum samples — Journal of chromatography. B, Analytical technologies in the biomedical and life sciences doi:10.1016/j.jchromb.2017.01.046
- [4]
- [5]
- [6]